Document Type : Short Communication
Authors
Department of Hematology, School of Para Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Abstract
Background: Heat shock proteins (HSPs) are involved in innate and adaptive immune responses, especially inflammatory responses due to immune cell activation. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was one of the most important causes of death in the recent pandemic. Increased cellular stress and excessive inflammation are common in coronavirus disease-19 (COVID-19), although the underlying mechanisms are still poorly
understood.
Objective: To evaluate the relationship between HSP and the pathological effects of COVID-19.
Methods: A group of 107 patients was categorized to two populations (mild and severe) based on their chest high-resolution computed tomography (HRCT) results. The HSP70, HSP90 alpha, and serum levels of C-reactive protein (CRP) were measured by enzyme-linked immunosorbent assay (ELISA). Lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) were measured by the automated analyzer.
Results: Our data showed increased levels of HSP70 and HSP90 in patients with COVID-19. The HSPs levels were elevated in the severe group compared to the mild group. This study demonstrated a positive correlation between both elevated levels of HSP70, HSP90, and HRCT grade and also a positive correlation with CRP and CPK in the severe group.
Conclusion: HSP90 and HSP70 contribute to excessive immune responses and cytokine storms. They may serve as prognostic serum markers for COVID-19 lung injury. Additionally, they are
candidates for anti-inflammatory therapy.
Keywords
- Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, et al. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. Journal of clinical medicine. 2020;9(4):941.
- Chen L-D, Zhang Z-Y, Wei X-J, Cai Y-Q, Yao W-Z, Wang M-H, et al. Association between cytokine profiles and lung injury in COVID-19 pneumonia. Respiratory Research. 2020;21(1):1-8.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
- Tobinick E. TNF-α inhibition for potential therapeutic modulation of SARS coronavirus infection. Current medical research and opinion. 2004;20(1):39-40.
- Santoro MG, Amici C, Rossi A. Role of heat shock proteins in viral infection. Prokaryotic and Eukaryotic Heat Shock Proteins in Infectious Disease: Springer; 2009. p. 51-84.
- Wan Q, Song D, Li H, He M-l. Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development. Signal transduction and targeted therapy. 2020;5(1):1-40.
- Bolhassani A, Agi E. Heat shock proteins in infection. Clinica Chimica Acta. 2019;498:90-100.
- Singh NK, Srivastava S, Zaveri L, Bingi TC, Mesipogu R, Kumar S, et al. Host transcriptional response to SARS-CoV-2 infection in COVID-19 patients. bioRxiv. 2021.
- Hong L-J, Chen A-J, Li F-Z, Chen K-J, Fang S. The HSP90 Inhibitor, 17-AAG, Influences the Activation and Proliferation of T Lymphocytes via AKT/GSK3β Signaling in MRL/lpr Mice. Drug Design, Development and Therapy. 2020;14:4605.
- Hulina-Tomašković A, Somborac-Bačura A, Rajković MG, Hlapčić I, Bosnar M, Rumora L. Effects of extracellular Hsp70, lipopolysaccharide and lipoteichoic acid on human monocyte-derived macrophages and differentiated THP-1 cells. Biological Chemistry. 2020;401(10):1181-90.
- Lechner P, Buck D, Sick L, Hemmer B, Multhoff G. Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis. Multiple Sclerosis Journal–Experimental, Translational and Clinical. 2018;4(2):2055217318767192.
- Zhang X-Y, Huang Z, Li Q-J, Zhong G-Q, Meng J-J, Wang D-X, et al. Role of HSP90 in suppressing TLR4-mediated inflammation in ischemic postconditioning. Clinical Hemorheology and Microcirculation. 2020(Preprint):1-12.
- Jiang Y, Guo D, Li C, Chen T, Li R. High-resolution CT features of the COVID-19 infection in Nanchong City: Initial and follow-up changes among different clinical types. Radiology of infectious diseases. 2020;7(2):71-7.
- Gracia-Hernandez M, Sotomayor EM, Villagra A. Targeting macrophages as a therapeutic option in COVID-19. Frontiers in pharmacology. 2020;11:1659.
- Paladino L, Vitale AM, Caruso Bavisotto C, Conway de Macario E, Cappello F, Macario AJ, et al. The role of molecular chaperones in virus infection and implications for understanding and treating COVID-19. Journal of clinical medicine. 2020;9(11):3518.
- Hacker S, Lambers C, Hoetzenecker K, Pollreisz A, Aigner C, Lichtenauer M, et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin Lab. 2009;55(1-2):31-40.
- Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, et al. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Molecular cancer therapeutics. 2019;18(3):531-40.
- Zangeneh Z, Andalib A, Khamisipour G, Saadabadimotlagh H, Zangeneh S, Motamed N. TNF-, iNOS Augmentation Due to Macrophages and Neutrophils Activity in Samples from Patients in Intensive Care Unit with COVID-19 Infection. International Journal of Medical Laboratory. 2021;8(4):247-55.
- Barone R, Marino Gammazza A, Paladino L, Pitruzzella A, Spinoso G, Salerno M, et al. Morphological alterations and stress protein variations in lung biopsies obtained from autopsies of COVID-19 subjects. Cells. 2021;10(11):3136.
- Wyler E, Mösbauer K, Franke V, Diag A, Gottula LT, Arsiè R, et al. Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy. IScience. 2021;24(3):102151.
- Goswami R, Russell VS, Tu JJ, Thomas C, Hughes P, Kelly F, et al. Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. Iscience. 2021;24(12):103412.
- Sultan I, Howard S, Tbakhi A. Drug repositioning suggests a role for the heat shock protein 90 inhibitor geldanamycin in treating COVID-19 infection. 2020.
- Saha A, Anirvan P. Cancer progression in COVID-19: integrating the roles of renin angiotensin aldosterone system, angiopoietin-2, heat shock protein-27 and epithelial mesenchymal transition. ecancermedicalscience. 2020;14.
- Shi L, Chevolot Y, Souteyrand E, Laurenceau E. Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer. Cancer Biomarkers. 2017;18(2):105-16.
)